Glycoprotein IIb/IIIa inhibitors: An update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy

Biomarkers in Medicine

Volumn 5, Issue 1, 2011, Pages 63-70

  Lippi, Giuseppe ^a   Montagnana, Martina ^b   Danese, Elisa ^b   Favaloro, Emmanuel J ^a   Franchini, Massimo ^c  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

glycoprotein IIb IIIa; monitoring; platelets; therapy; thrombosis

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN;

ACUTE CORONARY SYNDROME; BINDING COMPETITION; BLEEDING; DOSE RESPONSE; DRUG BINDING SITE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; RECEPTOR OCCUPANCY; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; THROMBOGENESIS; UNSTABLE ANGINA PECTORIS;

EID: 79951796382     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.10.119     Document Type: Review

References (66)

1. Calvete JJ: On the structure and function of platelet integrin αIIbβ3, the fibrinogen receptor. Proc. Soc. Exp. Biol. Med. 208, 346-360 (1995).
2. Nurden AT, Caen JP: An abnormal platelet glycoprotein pattern in three cases of Glanzmanns thrombasthenia. Br. J. Haematol. 28, 253-260 (1974).
3. Jennings LK, Phillips DR: Purification of glycoproteins IIb and III from human platelet plasma membranes and characterization of a calcium-dependent glycoprotein IIb-III complex. J. Biol. Chem. 257, 10458-10466 (1982). (Pubitemid 13252245)
4. Gulino D, Boudignon C, Zhang LY, Concord E, Rabiet MJ, Marguerie G: Ca2+-binding properties of the platelet glycoprotein IIb ligand-interacting domain. J. Biol. Chem. 267, 1001-1007 (1992).
5. Calvete JJ: Clues for understanding the structure and function of a prototypic human integrin: the platelet glycoprotein IIb/IIIa complex. Thromb. Haemost. 72, 1-15 (1994). (Pubitemid 24202287)
6. Bray PF, Barsh G, Rosa JP, Luo XY, Magenis E, Shuman MA: Physical linkage of the genes for platelet membrane glycoproteins IIb and IIIa. Proc. Natl Acad. Sci. USA 85, 8683-8687 (1988). (Pubitemid 19025021)
7. Heidenreich R, Eisman R, Surrey S et al.: Organization of the gene for platelet glycoprotein IIb. Biochemistry 29, 1232-1244 (1990). (Pubitemid 20053847)
8. Zimrin AB, Gidwitz S, Lord S et al.: The genomic organization of platelet glycoprotein IIIa. J. Biol. Chem. 265, 8590-8595 (1990).
9. Faull RJ, Du X, Ginsberg MH: Receptors on platelets. Methods Enzymol. 245, 183-194 (1994).
10. Vorchheimer DA, Badimon JJ, Fuster V: Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease. JAMA 281, 1407-1414 (1999). (Pubitemid 29190219)
11. Lewis JC, Hantgan RR, Stevenson SC et al.: Fibrinogen and glycoprotein IIb/IIIa localization during platelet adhesion. Localization to the granulomere and at sites of platelet interaction. Am. J. Pathol. 136, 239-252 (1990). (Pubitemid 20034970)
12. Coppolino MG, Dedhar S: Bi-directional signal transduction by integrin receptors. Int. J. Biochem. Cell. Biol. 32, 171-188 (2000). (Pubitemid 30001820)
13. Savage B, Ruggeri ZM: Selective recognition of adhesive sites in surface-bound fibrinogen by glycoprotein IIb-IIIa on nonactivated platelets. J. Biol. Chem. 266, 11227-11233 (1991). (Pubitemid 21906936)
14. Arya M, López JA, Romo GM et al.: Glycoprotein Ib-IX-mediated activation of integrin αIIbβ3: effects of receptor clustering and von Willebrand factor adhesion. J. Thromb. Haemost. 1, 1150-1157 (2003).
15. Payrastre B, Missy K, Trumel C, Bodin S, Plantavid M, Chap H: The integrin αIIbβ3 in human platelet signal transduction. Biochem. Pharmacol. 60, 1069-1074 (2000).
16. Yang J, Ma YQ, Page RC, Misra S, Plow EF, Qin J: Structure of an integrin αIIbβ3 transmembrane-cytoplasmic heterocomplex provides insight into integrin activation. Proc. Natl Acad. Sci. USA 106, 17729-17734 (2009).
17. Calvete JJ: Structures of integrin domains and concerted conformational changes in the bidirectional signaling mechanism of αIIbβ3. Exp. Biol. Med. (Maywood) 229, 732-744 (2004). (Pubitemid 39166477)
18. Kloczewiak M, Timmons S, Lukas TJ, Hawiger J: Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the γ-chain. Biochemistry 23, 1767-1774 (1984). (Pubitemid 14139817)
19. Yan B, Smith JW: A redox site involved in integrin activation. J. Biol. Chem. 275, 39964-39972 (2000). (Pubitemid 32064618)
20. Yan B, Smith JW: Mechanism of integrin activation by disulfide bond reduction. Biochemistry 40, 8861-8867 (2001). (Pubitemid 32709519)
21. Vanhoorelbeke K, De Meyer SF, Pareyn I et al.: The novel S527F mutation in the integrin β3 chain induces a high affinity αIIbβ3 receptor by hindering adoption of the bent conformation. J. Biol. Chem. 284, 14914-14920 (2009).
22. Luo BH, Karanicolas J, Harmacek LD, Baker D, Springer TA: Rationally designed integrin β3 mutants stabilized in the high affinity conformation. J. Biol. Chem. 284, 3917-3924 (2009).
23. Podolnikova NP, Yermolenko IS, Fuhrmann A et al.: Control of integrin αIIbβ3 outside-in signaling and platelet adhesion by sensing the physical properties of fibrin(ogen) substrates. Biochemistry 49, 68-77 (2010).
24. Senis YA, Antrobus R, Severin S et al.: Proteomic analysis of integrin αIIbβ3 outside-in signaling reveals Src-kinase-independent phosphorylation of Dok-1 and Dok-3 leading to SHIP-1 interactions. J. Thromb. Haemost. 7, 1718-1726 (2009).
25. Franchini M, Mannucci PM: New antiplatelet agents: why they are needed. Eur. J. Intern. Med. 20, 733-738 (2009).
26. Angiolillo DJ, Ueno M, Goto S: Basic principles of platelet biology and clinical implications. Circ. J. 74, 597-607 (2010).
27. De Meyer SF, Vanhoorelbeke K, Broos K, Salles II, Deckmyn H: Antiplatelet drugs. Br. J. Haematol. 142, 515-528 (2008). (Pubitemid 352020216)
28. Topol EJ, Byzova T, Plow EF: Of platelets, integrin αIIbβ3 and GPIIb-IIIa blockers: past, present and future perspectives. Lancet 353, 227-231 (1999).
29. Kong DF, Califf RM, Miller DP et al.: Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 98, 2829-2835 (1998). (Pubitemid 29003963)
30. Ernst NM, Suryapranata H, Miedema K et al.: Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol. 44, 1187-1193 (2004). (Pubitemid 39208872)
31. Meadows TA, Bhatt TL: Clinical aspects of platelet inhibition and thrombus formation. Circ. Res. 100, 1261-1275 (2007). (Pubitemid 46742917)
32. Neumann FJ, Zohlnhofer D, Fakhoury L, Ott I, Gawaz M, Shomig A: Effect of glycoprotein IIb/IIIa receptor blockade on platelet leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J. Am. Coll. Cardiol. 34, 1420-1426 (1999). (Pubitemid 29528652)
33. Dasgupta H BJ, Wood GC, Frey CM, Demko SL, Menapace FJ: Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am. Heart. J. 140, 206-211 (2000). (Pubitemid 30641579)
34. Topol EJ, Lincoff AM, Kereiakes DJ et al.: Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am. J. Med. 113, 1-6 (2002). (Pubitemid 34775153)
35. Cannon CP, Weintraub WS, Demopoulos LA et al.: Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N. Engl. J. Med. 344, 1879-1887 (2001). (Pubitemid 32564900)
36. Peterson ED, Pollack CV Jr, Roe MT et al.: Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction: observations from the National Registry of Myocardial Infarction 4. J. Am. Coll. Cardiol. 42, 45-53 (2003). (Pubitemid 36760759)
37. Investigators GI-A: Effect of GPpIIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndrome without early coronary revascularization: the GUSTO IV-ACS trial. Lancet 357, 1915-1924 (2001).
38. Kleiman NS: Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors. Am. Heart. J. 138, 263-275 (1999).
39. Quinn MJ, Plow EF, Topol EJ: Platelet glycoprotein IIb/IIIa inhibitors. Recognition of a two-edge sword? Circulation 106, 379-385 (2000).
40. Bolognese L, Falsini G, Liistro F et al.: Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial. J. Am. Coll. Cardiol. 47, 522-528 (2006). (Pubitemid 43170839)
41. Cannon CP, McCabe CH, Wilcox RG et al.: Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 102, 149-156 (2000) (Pubitemid 30451770)
42. ONeill WW, Serruys P, Knudtson M et al.: Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of oral xemilofiban in controlling thrombotic events. N. Engl. J. Med. 342, 1316-1324 (2000) (Pubitemid 30408716)
43. Second SYMPHONY Investigators: Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. Circulation 103, 1727-1733 (2001).
44. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes. Lancet 355, 337-345 (2000).
45. Chew DP, Bhatt DL, Sapp S, Topol EJ: Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of Phase III multicenter randomized trials. Circulation 103, 201-206 (2001). (Pubitemid 32095403)
46. Favaloro EJ, Lippi G, Franchini M: Contemporary platelet function testing. Clin. Chem. Lab. Med. 48, 579-598 (2010).
47. Favaloro EJ: Clinical utility of the PFA-100. Semin. Thromb. Hemost. 34, 709-733 (2008).
48. Galeote G, López Pastor A et al.: Variable response to the biological inhibition of platelets by abciximab in patients subjected to percutaneous coronary angioplasty. Rev. Esp. Cardiol. 54, 1256-1263 (2001). (Pubitemid 33130362)
49. Madan M, Berkowitz SD, Christie DJ et al.: Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. Am. Heart. J. 141, 226-233 (2001). (Pubitemid 32128727)
50. Madan M, Berkowitz SD, Christie DJ, Smit AC, Sigmon KN, Tcheng JE: Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100. Am. Heart. J. 144, 151-158 (2002). (Pubitemid 34734769)
51. Batchelor WB, Tolleson TR, Huang Y et al.: Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Circulation 106, 1470-1476 (2002).
52. Wu KK, Willerson JT: Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy. Circulation 103, 2528-2530 (2001). (Pubitemid 32521958)
53. Schafer AI: Genetic and acquired determinants of individual variability of response to antiplatelet drugs. Circulation 108, 910-911 (2003). (Pubitemid 37048214)
54. Lippi G, Favaloro EJ, Salvagno GL, Franchini M: Laboratory assessment and perioperative management of patients on antiplatelet therapy: from the bench to the bedside. Clin. Chim. Acta 405, 8-16 (2009).
55. Cattaneo M: Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. Semin. Thromb. Hemost. 35, 158-167 (2009).
56. Harrison P, Mumford A: Screening tests of platelet function: update on their appropriate uses for diagnostic testing. Semin. Thromb. Hemost. 35, 150-157 (2009).
57. Pai M, Hayward CP: Diagnostic assessment of platelet disorders: what are the challenges to standardization? Semin. Thromb. Hemost. 35, 131-138 (2009).
58. Deibele AJ, Jennings LK, Tcheng JE et al.: Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial. Circulation 121, 784-791 (2010).
59. van Werkum JW, Harmsze AM, Elsenberg EH, Bouman HJ, ten Berg JM, Hackeng CM: The use of the VerifyNow system to monitor antiplatelet therapy: a review of the current evidence. Platelets 19, 479-488 (2008).
60. Graff J, Harder S: Investigation of the PADA as a method for monitoring GPIIb/IIIa inhibitors and other antiplatelet agents. Semin. Thromb. Hemost. 31, 482-485 (2005). (Pubitemid 41362356)
61. Harrison P, Frelinger AL 3rd, Furman MI, Michelson AD: Measuring antiplatelet drug effects in the laboratory. Thromb. Res. 120, 323-336 (2007). (Pubitemid 46879909)
62. Schumann A, Bucha E, Nowak G: Is platelet adhesion assay able to quantify drug-induced platelet dysfunction? Semin. Thromb. Hemost. 31, 476-481 (2005). (Pubitemid 41362355)
63. Matzdorff A: Platelet function tests and flow cytometry to monitor antiplatelet therapy. Semin. Thromb. Hemost. 31, 393-399 (2005). (Pubitemid 41362343)
64. Stegnar M, Bozic M, Dolenc MS, Anderluh PS, Kikelj D: Utility of PFA-100 closure time vs. optical aggregometry in assessing the efficacy of platelet membrane glycoprotein IIb/IIIa antagonists in vitro. Clin. Chem. Lab. Med. 45, 1542-1548 (2007). (Pubitemid 350036573)
65. Campo G, Valgimigli M, Gemmati D et al.: Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study. J. Am. Coll. Cardiol. 48, 2178-2185 (2006). (Pubitemid 44873056)
66. Steinhubl SR, Talley JD, Braden GA et al.: Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU - Assessing Ultegra) multicenter study. Circulation 103, 2572-2578 (2001). (Pubitemid 32521967)